Related Experiment Videos

Hypertension: possible differential risk for blacks in Beta-Blocker Heart Attack Trial (BHAT)

L J Haywood1

  • 1University of Southern California School of Medicine, Los Angeles.

Insights

Beta-blockers reduce mortality after heart attack. This study highlights how high blood pressure in Black patients in the Beta-Blocker Heart Attack Trial (BHAT) contributed to higher risk and similar treatment responses as other high-risk groups.

Area of Science:

  • Cardiology
  • Clinical Trials
  • Pharmacology

Background:

  • Beta-adrenergic antagonists are proven to reduce mortality post-acute myocardial infarction.
  • Higher mortality rates were observed among Black patients in the Beta-Blocker Heart Attack Trial (BHAT).

Purpose of the Study:

  • To emphasize the role of pre-existing hypertension in the elevated risk profile of Black patients within the BHAT.
  • To examine the response to beta-blocker therapy in high-risk Black patients compared to other high-risk participants.

Main Methods:

  • Analysis of data from the Beta-Blocker Heart Attack Trial (BHAT).
  • Focus on patient subgroups, specifically Black patients with prior high blood pressure.
  • Comparison of treatment response across different risk profiles.

Main Results:

  • Prior high blood pressure is identified as a significant factor in the high-risk profile of Black patients in BHAT.
  • Black patients with hypertension showed a similar response to beta-blocker therapy as other high-risk patients in the trial.

Conclusions:

  • Hypertension plays a crucial role in the cardiovascular risk of Black patients post-myocardial infarction.
  • Beta-blocker efficacy in reducing mortality is consistent across various high-risk patient groups, including Black patients with hypertension.

Related Concept Videos